Neither Tumor-Infiltrating Lymphocytes nor Cytotoxic T Cells Predict Enhanced Benefit from Chemotherapy in the DBCG77B Phase III Clinical Trial

Keyphrases

• Chemotherapy 100%
• Phase III Clinical Trial 100%
• Tumor-infiltrating Lymphocytes 100%
• Cytotoxic T Cells 100%
• Programmed Death-ligand 1 (PD-L1) 40%
• Immune Markers 40%
• High Risk 20%
• Hazard Ratio 20%
• Cyclophosphamide 20%
• Immunohistochemistry 20%
• Disease-free Survival 20%
• Forkhead Box P3 (FOXP3) 20%
• Patient Benefit 20%
• Statistical Plan 20%
• Interaction Test 20%
• Kaplan-Meier 20%
• Survival Probability 20%
• Early Breast Cancer 20%
• Postmenopausal Women 20%
• Cytotoxic Chemotherapy 20%
• Hematoxylin 20%
• Eosin 20%
• Primary Tumor 20%
• Cox Proportional Hazards 20%
• Reporting Guidelines 20%
• Immune Infiltration 20%
• Breast Cancer Subtypes 20%
• Response to Therapy 20%
• Invasive Disease 20%
• Tissue Microarray 20%
• Ratio Analysis 20%
• Improved Prognosis 20%
• Tumor Microenvironment 20%
• Stromal Tumor-infiltrating Lymphocytes 20%
• CD-8 20%

Immunology and Microbiology

• Tumor-Infiltrating Lymphocytes 100%
• Cytotoxic T Cell 100%
• CD8 33%
• Programmed Death-Ligand 1 33%
• Cyclophosphamide 33%
• Disease Free Survival 33%
• Immune Cell Infiltration 33%
• Premenopause 33%
• FOXP3 33%
• Morphology 33%